We therefore examined the effects of pyrvinium, dasatinib or the combination on CD34+ cells isolated from BP-CML patients or from cord blood (patient clinical information is in Supplemental Table 1). The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.